Ikarian Capital’s BridgeBio Pharma BBIO Stock Holding History

Ikarian Capital’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.34M	Buy	+58,500	New	+$4.24M	0.35%	65
2025 Q2	–	Sell	-655,400	Closed	-$22.7M	–	140
2025 Q1	$22.7M	Sell	655,400 -44,600	-6%	-$1.5M	2.79%	5
2024 Q4	$19.2M	Buy	+700,000	New	+$18.1M	2.61%	7
2024 Q3	–	Sell	-6,000	Closed	-$15.2M	–	156
2024 Q2	$15.2M	Sell	6,000 -383,400	-98%	-$10.5M	2.65%	11
2024 Q1	$12M	Buy	+389,400	New	+$13.2M	1.32%	22
2023 Q4	–	Sell	-3,054	Closed	-$8.05M	–	143
2023 Q3	$8.05M	Sell	3,054 -1,226,746	-100%	-$34.8M	0.97%	31
2023 Q2	$21.2M	Buy	1,229,800 +680,200	+124%	+$10.2M	3.37%	3
2023 Q1	$9.11M	Buy	+549,600	New	+$6.41M	2.07%	11
2022 Q3	–	Sell	-200,000	Closed	-$1.82M	–	115
2022 Q2	$1.82M	Buy	+200,000	New	+$1.67M	0.33%	62
2022 Q1	–	Sell	-100,000	Closed	-$1.67M	–	200
2021 Q4	$1.67M	Buy	+100,000	New	+$4.23M	0.25%	74
2020 Q3	–	Sell	-31,500	Closed	-$1.03M	–	181
2020 Q2	$1.03M	Buy	+31,500	New	+$959K	0.08%	123

Other funds holding BBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ikarian Capital's BBIO Position: Q1 2026 in Review

Ikarian Capital opened a new position in BridgeBio Pharma (BBIO) in Q1 2026: 160,120 shares worth $11.9M. The stake represents 0.97% of the portfolio and ranks #25 among its holdings. This is a return to the name: Ikarian Capital previously reported a position in BBIO as recently as Q3 2025.

Ikarian Capital first reported a position in BBIO in Q1 2020 and has held it in 13 quarters since. The position peaked at $19.1M in Q4 2023. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

Ikarian Capital held 160,120 shares of BridgeBio Pharma worth $11.9M as of Q1 2026.
BridgeBio Pharma was a new Ikarian Capital position in Q1 2026.
BridgeBio Pharma made up 0.97% of Ikarian Capital's portfolio in Q1 2026, its #25 holding.
Ikarian Capital first reported a position in BridgeBio Pharma in Q1 2020 and has held it in 13 quarters since.
Ikarian Capital's BridgeBio Pharma position peaked at $19.1M in Q4 2023.
457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.